Fierce Pharma

MARCH 24, 2023

Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst kdunleavy Fri, 03/24/2023 - 07:30

Sales 278

Sales 278

PM360

MARCH 24, 2023

Technology evolves fast. Nothing illustrates that better than attending SXSW each year and noticing how much has changed in just 12 months. In 2022, SXSW was all NFTs and metaverse activations and events, and in 2023 they weren’t anywhere to be found. But a lot was shared at this year’s SXSW that had staying power. In place of NFTs, psychedelics were given their own conference track this year.

Media 119

Media Engineering Healthcare Healthcare 119

Fierce Pharma

MARCH 24, 2023

GSK plays defense after California judge approves plaintiff's expert testimony in high-stakes Zantac trial fkansteiner Fri, 03/24/2023 - 10:05

287

287

European Pharmaceutical Review

MARCH 24, 2023

Following the recent announcement of topline results from 89bio’s Phase IIb trial, ENLIVEN, evaluating FGF21 analogue pegozafermin for nonalcoholic steatohepatitis (NASH), a serious liver condition, EPR spoke with Dr Hank Mansbach, the company’s Chief Medical Officer. NASH currently has no approved treatments. Caused by excess fat, it is referred to as the ‘silent killer’, as most affected individuals don’t exhibit symptoms until liver damage has already occurred.

Medical 108

Medical Side effects Safety Patients 108

Advertisement

Fierce Pharma

MARCH 24, 2023

Brii Bio shelves once-promising COVID antibody combo that stood up to variants kdunleavy Fri, 03/24/2023 - 10:07

257

257

PM360

MARCH 24, 2023

Cancer-support programs provide vital assistance to patients and their caregivers as they face one of the toughest times of their lives. Yet while patients are interested in these programs, new survey data suggests they aren’t taking advantage of them. Results from 825 patients diagnosed with or treated for cancer who were surveyed on Phreesia’s PatientInsights platform as they checked in for their doctors’ appointments revealed that few cancer patients are accessing the support resources availa

Patients 98

Patients Education Side effects Media 98

PM360

MARCH 24, 2023

Unacknowledged personal biases in the workplace can quickly spiral, leaving employees feeling alienated and disengaged. This has far-reaching implications that can also influence external brand experiences with target stakeholders. In the healthcare industry, this is especially concerning as it can contribute to health disparities and impact progress toward health equity : better health and well-being for all.

Healthcare 96

Healthcare Healthcare Education Leads 96

Fierce Pharma

MARCH 24, 2023

With rejection for slow-release Jakafi, FDA sends shockwaves across Incyte's pipeline: analyst aliu Fri, 03/24/2023 - 10:04

FDA 147

FDA 147

European Pharmaceutical Review

MARCH 24, 2023

The European Medicines Agency (EMA) has published a report summarising the mid-point achievements of its Regulatory Science Strategy (RSS) to 2025. Initially published in March 2020, the strategy provides a plan for advancing regulatory science over a five-year period. Regulatory science refers to the scientific disciplines that are applied to the quality, safety and efficacy assessment of medicinal products.

Medicine 96

Medicine Consulting Networking Safety 96

PM360

MARCH 24, 2023

Drug price transparency (DPT) laws have been in effect in several states for a few years now. Starting with Vermont in 2016, more than half of the U.S. states are now collecting pricing data from manufacturers in the hopes it will assist in creating effective policies to reduce drug prices for their constituents. The question of whether this goal will be realized or not remains unanswered for now.

Manufacturing 96

Manufacturing Retail Management Marketing 96

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

MARCH 24, 2023

Oak Street Health teamed up with kidney care management company Interwell Health to create a joint venture called OakWell, which seeks to provide primary care to end-stage kidney disease patients directly in existing dialysis centers. End stage kidney disease patients spend upwards of 12 hours per week in dialysis centers — OakWell is meant to eliminate the barrier of attending separate, additional medical appointments.

Management 110

Management Medical Patients 110

PM360

MARCH 24, 2023

Let’s talk digital transformation! In January, I started my series by identifying five key components of a successful digital transformation. We covered the first one by looking at Organizational Structures , today, let’s dive into the second which is the toughest, not just for pharma, but for the entire country: Diversity, Equity, and Inclusion (DE&I).

Pharma 94

Pharma Education Digital Media Media 94

MedCity News

MARCH 24, 2023

About 28% of Americans consider themselves to be caregivers, and 22% are unpaid, according to a new survey from CVS Health and Harris Poll. These caregivers are facing financial and mental health struggles: 47% said that being a caregiver is a financial burden and 49% said their mental health suffers from being a caregiver.

112

112

PM360

MARCH 24, 2023

Pharma marketers often turn to disease awareness days, weeks, and months to inform campaigns as they strategize for the year ahead. With the sheer number of official awareness days out there, it’s no wonder they’ve become a pillar to a marketer’s early plan development. To the pharma marketing industry, these days and months present a clear opportunity to shed light on a particular condition or therapeutic area.

Media 92

Media Education Pharma Networking 92

Advertisement

Distribution

MedCity News

MARCH 24, 2023

These are challenging times for health care, and particularly for women in health care.

121

121

Copyright Clearance Center

MARCH 24, 2023

The post At London Book Fair, Spotlight on Ukraine appeared first on Copyright Clearance Center.

98

98

MedCity News

MARCH 24, 2023

Flare Therapeutics, EpiBiologics, and Mbiomics are among the biotech companies that recently unveiled new rounds of financing.

Biopharma 113

Biopharma Pharma 113

PharmaVoice

MARCH 24, 2023

How life science execs would transform clinical trials with a little hocus pocus.

Pharma 98

Pharma 98

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

MedCity News

MARCH 24, 2023

Check out news from OUI Medical, Vital, Cognito Therapeutics and Reveal HealthTech.

Healthcare 125

Healthcare Healthcare Medical 125

Pharmaceutical Technology

MARCH 24, 2023

Biosimilars for AbbVie’s (US) Humira (adalimumab) have finally launched in the US, bringing an end to Humira’s 20-year reign as the best-selling biologic of all time. Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Amgen’s (US) Amjevita (adalimumab) is the first Humira biosimilar, launched in February 2023, and seven other FDA-approved biosimilars are expected to arrive on the US market later this year.

Competition 59

Competition Marketing FDA Physicians 59

Pharmaceutical Commerce

MARCH 24, 2023

Pharma Commerce offers a synopsis of some of the conference’s events.

Pharma 96

Pharma 96

PharmaTimes

MARCH 24, 2023

21GRAMS takes four Golds plus Best in Show AstraZeneca tops the pharma leader board

Pharma 82

Pharma 82

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Medico Reach

MARCH 24, 2023

The American Cancer Society estimates 1,958,310 new cases of cancer in the United States in 2023. As a result, a global approach to healthcare has emerged continually over the years. Even for cancers that are difficult to treat, new treatments and technologies improve patient survival rates. Hence, new oncology market trends will set in as doctors and pharmaceutical companies work towards individualized treatment decisions.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Legacy MEDSearch

MARCH 24, 2023

Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure (HF), announced that patients treated with the investigational AccuCinch ® Ventricular Restoration System demonstrated improvement in HF patient outcomes and beneficial changes in the structure of the heart. The 12-month data were presented as part of a late-breaking clinical science session at the Technology and Heart Failure Therapeutics conference (THT 2023) and simultaneously pu

Patients 52

Patients Recruitment Medical Medicine 52

Medico Reach

MARCH 24, 2023

The American Cancer Society estimates 1,958,310 new cases of cancer in the United States in 2023. As a result, a global approach to healthcare has emerged continually over the years. Even for cancers that are difficult to treat, new treatments and technologies improve patient survival rates. Hence, new oncology market trends will set in as doctors and pharmaceutical companies work towards individualized treatment decisions.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Pharmaceutical Technology

MARCH 24, 2023

Moderna has entered a strategic partnership with Generation Bio for the development of non-viral genetic medicines. Moderna’s biological and technical expertise will be combined with core technologies of the non-viral genetic medicine platform from Generation Bio. The collaboration aims to expand each company’s platform application through the development of new nucleic acid therapeutics, and to expedite their respective non-viral genetic medicines pipelines.

Medicine 52

Medicine Sales Patients 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

PharmaTimes

MARCH 24, 2023

The multi-centre international clinical trial will evaluate company’s Debio 0328 candidate

68

68

Pharmaceutical Technology

MARCH 24, 2023

Takeda has unveiled plans to invest almost $764m (JPY100bn) to construct a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. The new facility represents the company’s largest-ever investment in the expansion of manufacturing capacity in the country. It is expected to become the largest facility in Japan and to increase the company’s current plasma manufacturing site capacity in Narita almost five-fold.

Manufacturing 52

Manufacturing Networking Patients Pharma 52

PharmExec

MARCH 24, 2023

The partnership was sealed to support U.S. launch & commercialization of a medical device to help cancer patients manage and treat oral mucositis.

Management 52

Management Medical Patients 52

PharmaTimes

MARCH 24, 2023

Study shows significant reduction of nasal S.

Patients 87

Patients 87

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization